Vantage logo

Biotech catalysts on the horizon

The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.

Vantage logo

Biohaven’s high-risk bet

There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.

Vantage logo

Glaxo holds its breath

A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.